Literature DB >> 28247031

Benefit on motor and non-motor behavior in a specialized unit for Parkinson's disease.

Thomas Müller1, Gabi Öhm2, Kathrin Eilert2, Katharina Möhr2, Stephanie Rotter2, Thomas Haas2, Matthias Küchler2, Sven Lütge2, Marion Marg2, Hartmut Rothe2.   

Abstract

Treatment of patients with Parkinson's disease in specialized units is quite common in Germany. Data on the benefit of this hospitalization of patients with Parkinson's disease on motor and non-motor symptoms in conjunction with standardized tests are rare. Objective was to determine the efficacy of this therapeutic setting. We scored disease severity and performed clinical tests, respectively, instrumental procedures under standardized conditions in consecutively referred in-patients initially and at the end of their hospital stay. There was a decrease of motor and non-motor symptoms. The extent of improvement of non-motor and motor symptoms correlated to each other. Performance of complex movement sequences became better, whereas execution of simple movement series did not ameliorate. The interval for the timed up and go test went down. We demonstrate the effectiveness of an in-patient stay in a specialized unit for Parkinson's disease. Objective standardized testing supplements subjective clinical scoring with established rating scales.

Entities:  

Keywords:  Motor behavior; Non-motor symptoms; Parkinson’s disease; Peg insertion; Tapping

Mesh:

Year:  2017        PMID: 28247031     DOI: 10.1007/s00702-017-1701-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  11 in total

1.  Correlation between tapping and inserting of pegs in Parkinson's disease.

Authors:  T Müller; S Schäfer; W Kuhn; H Przuntek
Journal:  Can J Neurol Sci       Date:  2000-11       Impact factor: 2.104

2.  Quality of life, caregiver burden and insurance in patients with Parkinson's disease in Germany.

Authors:  T Müller; D Woitalla
Journal:  Eur J Neurol       Date:  2010-11       Impact factor: 6.089

3.  The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

4.  International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

Review 5.  [Wearable Technique for the Assessment of Parkinson Symptoms: What's the Future?].

Authors:  W Maetzler; R Krüger; T Müller; W Oertel; P Urban; T Warnecke; J Klucken
Journal:  Fortschr Neurol Psychiatr       Date:  2016-06-08       Impact factor: 0.752

6.  Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Authors:  Thomas Müller
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

7.  Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.

Authors:  Thomas Müller; Birgit Voss; Kerstin Hellwig; Franz Josef Stein; Thorsten Schulte; Horst Przuntek
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Quantitation of non-motor symptoms in Parkinson's disease.

Authors:  K Ray Chaudhuri; P Martinez-Martin
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

9.  The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

Authors:  D Berg; J Godau; K Seppi; S Behnke; I Liepelt-Scarfone; S Lerche; H Stockner; A Gaenslen; P Mahlknecht; H Huber; K Srulijes; J Klenk; K Fassbender; W Maetzler; W Poewe
Journal:  Eur J Neurol       Date:  2012-08-01       Impact factor: 6.089

10.  The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease.

Authors:  Cris Zampieri; Arash Salarian; Patricia Carlson-Kuhta; Kamiar Aminian; John G Nutt; Fay B Horak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-02       Impact factor: 10.154

View more
  11 in total

1.  Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.

Authors:  Daniel Richter; Dirk Bartig; Wolfgang Jost; Christoph Jörges; Britta Stumpe; Ralf Gold; Christos Krogias; Lars Tönges
Journal:  J Neural Transm (Vienna)       Date:  2019-06-20       Impact factor: 3.575

2.  Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-02-01       Impact factor: 3.575

Review 3.  Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.

Authors:  Peter Riederer; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-03-22       Impact factor: 3.575

Review 4.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

5.  An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.

Authors:  Rejko Krüger; Paul Lingor; Triantafyllos Doskas; Johanna M L Henselmans; Erik H Danielsen; Oriol de Fabregues; Alessandro Stefani; Sven-Christian Sensken; Juan Carlos Parra; Koray Onuk; Ashley Yegin; Angelo Antonini
Journal:  Adv Ther       Date:  2017-06-19       Impact factor: 3.845

Review 6.  Safinamide: an add-on treatment for managing Parkinson's disease.

Authors:  Thomas Müller
Journal:  Clin Pharmacol       Date:  2018-04-05

7.  Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010⁻2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers.

Authors:  Daniel Richter; Dirk Bartig; Siegfried Muhlack; Elke Hartelt; Raphael Scherbaum; Aristeides H Katsanos; Thomas Müller; Wolfgang Jost; Georg Ebersbach; Ralf Gold; Christos Krogias; Lars Tönges
Journal:  Cells       Date:  2019-02-11       Impact factor: 6.600

Review 8.  View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?

Authors:  Thomas Müller
Journal:  Biologics       Date:  2021-07-29

Review 9.  Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany.

Authors:  Tino Prell; Frank Siebecker; Michael Lorrain; Carsten Eggers; Stefan Lorenzl; Jochen Klucken; Tobias Warnecke; Carsten Buhmann; Lars Tönges; Reinhard Ehret; Ingmar Wellach; Martin Wolz
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

10.  Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-08-19       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.